OncoSec Medical Announces New Phase II Trial in Head and Neck Cancer Using ImmunoPulse
Print
Alert
Oncosec Medical Incorporated (QB) (USOTC:ONCS)
Intraday Stock Chart
Today : Tuesday 9 December 2014
Click Here for more Oncosec Medical Incorporated (QB) Charts.
Multi-center Study to Expand Pipeline Beyond Skin Cancers
OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, has initiated a Phase II trial in squamous cell carcinoma of the head and neck (SCCHN) using its proprietary ImmunoPulse platform. The multicenter study is scheduled to be initiated in the first quarter of 2015, with the University of California San Francisco, under the direction of Dr. Alain Algazi as the first site of enrollment.
The study will enroll patients with treatment-refractory metastatic and unresectable SCCHN, regardless of HPV status. Eligible patients will receive up to nine cycles of IL-12 ImmunoPulse at six-week intervals and will be followed for clinical response and safety. The first stage of the study will enroll 20 patients with measurable disease. If three or more objective responses are observed, an additional 11 patients with measurable disease will be treated, for a total of 31 patients. The primary endpoint for this study will be best overall response by RECIST 1.1.